Gill J, Gorlick R (2021) Advancing therapy for osteosarcoma. Nat Rev Clin Oncol 18(10):609–624

Article  PubMed  Google Scholar 

Baud’huin M, Colleville E, Thepault RA, Orgebin E, Lamoureux F, Ory B (2024) Ribosome heterogeneity and RNA polI inhibition in osteosarcoma heterogeneity. Cancer Res 84(6Supplement):5471–5471

Article  Google Scholar 

Jiang Y, Wang J, Sun M, Zuo D, Wang H, Shen J, Jiang W, Mu H, Ma X, Yin F, Lin J, Wang C, Yu S, Jiang L, Lv G, Liu F, Xue L, Tian K, Wang G, Zhou Z, Lv Y, Wang Z, Zhang T, Xu J, Yang L, Zhao K, Sun W, Tang Y, Cai Z, Wang S, Hua Y (2022) Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. Nat Commun 13(1):7207

Article  PubMed  PubMed Central  Google Scholar 

Meltzer PS, Helman LJ (2021) New Horizons in the Treatment of Osteosarcoma. N Engl J Med 385(22):2066–2076

Article  PubMed  Google Scholar 

Tang D, Zeng T, Wang Y, Cui H, Wu J, Zou B, Tao Z, Zhang L, Garside GB, Tao S (2020) Dietary restriction increases protective gut bacteria to rescue lethal methotrexate-induced intestinal toxicity. Gut Microbes 12(1):1714401

Article  PubMed  PubMed Central  Google Scholar 

Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T (2020) Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol 21(4):593–602

Article  PubMed  Google Scholar 

Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne M, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Ovlisen AK, McIlroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O’Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Strussmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, El Galaly TC, Ferreri AJM, Cwynarski K, McKay P (2022) Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood 139(16):2499–2511

Article  PubMed  Google Scholar 

Maagdenberg H, Oosterom N, Zanen J, Gemmati D, Windsor RE, Heil SG, Esperon P, Jabeen S, Ruiz-Arguelles GJ, Zolk O, Hoerning S, Sleurs C, Lopez-Lopez E, Moreno-Galvan M, van den Heuvel-Eibrink MM, Maitland-van, der Zee AH, Carleton BC (2021) Genetic variants associated with methotrexate-induced mucositis in cancer treatment: A systematic review and meta-analysis. Crit Rev Oncol Hematol 161:103312

Taylor ZL, Mizuno T, Punt NC, Baskaran B, Navarro Sainz A, Shuman W, Felicelli N, Vinks AA, Heldrup J, Ramsey LB (2020) MTXPK.org: a clinical decision Support Tool evaluating high-dose Methotrexate Pharmacokinetics to inform Post-infusion Care and Use of Glucarpidase. Clin Pharmacol Ther 108(3):635–643

Article  PubMed  PubMed Central  Google Scholar 

Oude Munnink T, van der Meer A, de Haan J, Touw D, van Kruchten M (2019) Reversible impaired methotrexate Clearance after Platinum-based chemotherapy for Osteosarcoma. Ther Drug Monit 41(6):693–695

Article  PubMed  Google Scholar 

Sirotnak FM, Moccio DM, Dorick DM (1978) Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 38(2):345–353

PubMed  Google Scholar 

Simon N, Marsot A, Villard E, Choquet S, Khe HX, Zahr N, Lechat P, Leblond V, Hulot JS (2013) Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenomics J 13(6):507–513

Article  PubMed  Google Scholar 

Hui KH, Chu HM, Fong PS, Cheng WTF, Lam TN (2019) Population Pharmacokinetic Study and Individual Dose adjustments of high-dose methotrexate in Chinese Pediatric patients with Acute Lymphoblastic Leukemia or Osteosarcoma. J Clin Pharmacol 59(4):566–577

Article  PubMed  Google Scholar 

Kawakatsu S, Nikanjam M, Lin M, Le S, Saunders I, Kuo DJ, Capparelli EV (2019) Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol 84(6):1339–1348

Article  PubMed  Google Scholar 

Ghannoum M, Roberts DM, Goldfarb DS, Heldrup J, Anseeuw K, Galvao TF, Nolin TD, Hoffman RS, Lavergne V, Meyers P, Gosselin S, Botnaru T, Mardini K, Wood DM (2022) workgroup E Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol 17(4):602–622

Euteneuer AM, Seeger-Nukpezah T, Nolte H, Henjakovic M (2019) Estrogen receptor alpha (ERalpha) indirectly induces transcription of human renal organic anion transporter 1 (OAT1). Physiol Rep 7(21):e14229

Article  PubMed  PubMed Central  Google Scholar 

Gao X, Qian XW, Zhu XH, Yu Y, Miao H, Meng JH, Jiang JY, Wang HS, Zhai XW (2021) Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric patients with Acute Lymphoblastic Leukemia. Front Pharmacol 12:701452

Article  PubMed  PubMed Central  Google Scholar 

Valade S, Mariotte E, Azoulay E, Darmon M (2020) High-dose methotrexate in ICU patients: a retrospective study. Ann Intensive Care 10(1):81

Article  PubMed  PubMed Central  Google Scholar 

Kanarek N, Keys HR, Cantor JR, Lewis CA, Chan SH, Kunchok T, Abu-Remaileh M, Freinkman E, Schweitzer LD, Sabatini DM (2018) Histidine catabolism is a major determinant of methotrexate sensitivity. Nature 559(7715):632–636

Article  PubMed  PubMed Central  Google Scholar 

Svanstrom H, Lund M, Melbye M, Pasternak B (2018) Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf 27(8):885–893

Article  PubMed  Google Scholar 

Schulte RR, Choi L, Utreja N, Van Driest SL, Stein CM, Ho RH (2021) Effect of SLCO1B1 polymorphisms on high-dose methotrexate clearance in children and young adults with leukemia and Lymphoblastic Lymphoma. Clin Transl Sci 14(1):343–353

Article  PubMed  Google Scholar 

Toksvang LN, Lee SHR, Yang JJ, Schmiegelow K (2022) Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia 36(7):1749–1758

Article  PubMed  PubMed Central  Google Scholar 

Wang YC, Wu MT, Tang FY, Chen DY, Ko HA, Shane B, Huang WN, Chiang EP (2019) MTHFR C677T polymorphism increases MTX sensitivity via the inhibition of S-adenosylmethionine and de novo purine synthesis. Clin Sci (Lond) 133(2):253–267

Article  PubMed  Google Scholar 

Umerez M, Gutierrez-Camino A, Munoz-Maldonado C, Martin-Guerrero I, Garcia-Orad A (2017) MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy. Pharmgenomics Pers Med 10:69–78

PubMed  PubMed Central  Google Scholar 

Yang L, Hu X, Xu L (2012) Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol 33(5):1445–1454

Article  PubMed  Google Scholar 

Zhang C, Zhai S, Yang L, Wu H, Zhang J, Ke X (2010) Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia. Int J Clin Pharmacol Ther 48(1):11–21

Article  PubMed  Google Scholar 

Mei S, Li X, Jiang X, Yu K, Lin S, Zhao Z (2018) Population Pharmacokinetics of High-Dose Methotrexate in patients with primary Central Nervous System Lymphoma. J Pharm Sci 107(5):1454–1460

Article  PubMed  Google Scholar 

Desoky ESE, Ghazal MH, Singh RP, Abdelhamid ON, Derendorf H (2013) Population pharmacokinetics of methotrexate in Egyptian children with lymphoblastic leukemia

Gallais F, Oberic L, Faguer S, Tavitian S, Lafont T, Marsili S, Brice A, Chatelut E, Puisset F (2021) Body surface area dosing of high-dose Methotrexate should be reconsidered, particularly in overweight, adult patients. Ther Drug Monit 43(3):408–415

Article  PubMed  Google Scholar 

Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P Jr., Ward D, Gajjar A, Stewart CF (2015) Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol 75(1):27–35

Article  PubMed  Google Scholar 

Pai MP, Debacker KC, Derstine B, Sullivan J, Su GL, Wang SC (2020) Comparison of body size, Morphomics, and kidney function as covariates of high-dose methotrexate clearance in obese adults with primary Central Nervous System Lymphoma. Pharmacotherapy 40(4):308–319

Article  PubMed  PubMed Central  Google Scholar 

Yang L, Wu H, de Winter BCM, Sheng CC, Qiu HQ, Cheng Y, Chen J, Zhao QL, Huang J, Jiao Z, Xie RX (2020) Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-hodgkin lymphoma: a population analysis. Cancer Chemother Pharmacol 85(5):881–897

Article  PubMed  Google Scholar 

Fukuhara K, Ikawa K, Morikawa N, Kumagai K (2008) Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther 33(6):677–684

Article  PubMed  Google Scholar 

Zhang W, Zhang Q, Tian X, Zhao H, Lu W, Zhen J, Niu X (2015) Population pharmacokinetics of high-dose methotrexat